All men over 50 should be screened for prostate cancer, US experts say

Professor Andrew Wolf of the University of Virginia chaired the expert panel behind the American Cancer Society’s first update of its guidelines since 2010.

“For the first time, we are proactively recommending that men screen for prostate cancer using a prostate-specific antigen blood test,” he said.

Prostate cancer is the most commonly diagnosed cancer in the UK. Each year, more than 64,000 men are diagnosed and more than 12,000 die from the disease. Black men are about twice as likely to die from the disease as white men.

Under new US guidelines, a man whose father, brother or son was diagnosed before age 65 should have an annual check-up starting at age 45. The same applies if two or more of his relatives develop prostate cancer at any age.

In Britain, the National Screening Committee has recommended testing every two years for men aged 45 to 61 who carry a faulty BRCA2 gene and have a relevant family history.

Despite calls from experts to expand screening, the committee said broader testing could do more harm than good.

U.S. experts have said medical advances have reduced those risks. Doctors can better distinguish men who need a biopsy or treatment from those who can be safely monitored.

Dr. Robert Smith, the company’s senior vice president for early cancer detection science, said: “The PSA test is only the first step in a screening process. »

The blood test measures levels of prostate-specific antigen (PSA), a protein made by the prostate. A high reading can have several causes, which is why U.S. guidelines recommend a second test to verify the result for men ages 45 to 74.

“If men and their healthcare providers follow these recommendations, I am confident that we will see a decline in prostate cancer deaths and metastatic disease in the years to come,” Professor Wolf said.

“Evidence constantly examined”

David James, of Prostate Cancer Research, said the US decision followed a change in Australia, where doctors are now advised to discuss the PSA test with men aged 50 to 69. These conversations should start earlier for men at higher risk.

He added: “Both looked at the same evidence available to the UK National Selection Committee and came to very different conclusions.

“Here in the UK, even a man whose father and brother both had prostate cancer is not eligible for screening unless he also has a known BRCA2 variant.”

A spokesperson for the Department of Health and Social Care said: “The UK’s independent National Screening Committee is reviewing all the evidence in this area and will continue to review any new research as it emerges.

“Meanwhile, we have already started work to launch the first targeted prostate cancer screening program in England, aimed at men most at risk. We are also investing more than £30 million in prostate cancer research to improve diagnosis, treatment and screening.”

Gn Health

Logo